These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy.
    Author: Feiks A, Grünberger W, Meisner W.
    Journal: Am J Hypertens; 1991 Feb; 4(2 Pt 2):200S-202S. PubMed ID: 1827022.
    Abstract:
    Nine pregnant women (aged 28.7 +/- 6.9 years) who had developed hypertension (blood pressure greater than 140/90 mm Hg) took part in an open pilot study with the new calcium antagonist isradipine. Dosage was started with 1.25 mg twice daily and was increased weekly to 2.5 mg and 5 mg twice daily until a diastolic blood pressure of less than or equal to 80 mm Hg was achieved. By the time of the last visit before term, blood pressure was significantly reduced to 129/79 mm Hg and heart rate had not altered. External cardiotocography indicated fetal well-being throughout the entire study. Doppler flow measurements showed no deterioration in A:B ratio, resistance index, and pulsatile index. All measurements in the newborn were within normal ranges. In conclusion, isradipine is a safe and effective drug for pregnant women and their fetuses in the management of hypertensive disorders in pregnancy.
    [Abstract] [Full Text] [Related] [New Search]